The combination of the p53MVA vaccine with anti-PD-1 pembrolizumab in patients with advanced solid tumors including breast cancer resulted in disease control in 3/11 patients with 2 showing higher and more durable p53-reactive CD8+ T cells. Here, CD8A is linked to breast carcinoma.